[Clinical value of thrombocyte aggregation inhibitors during massive-dose estrogen therapy].
Due to an advanced prostatic carcinoma 166 patients were given a massive dose of oestrogen over a period of 10 days (6 g Honvan i.v.). A retrospective comparison of a control group of 94 patients without prophylaxis against thrombosis and a control group of 36 patients having received Heparin-Dihydergot did not show a significant difference of cardiovascular complications. Therefore, further 36 patients received a thrombocyte aggregation inhibitor (Godamed) as prophylaxis against embolic thrombosis. At the same time lung perfusion scintigraphy (99m Tc-Microspheres) was made directly before and after oestrogen therapy. Clinically and lung scintigraphically there was no different thromboembolic incidence compared to the patients given a Heparin-Dihydergot prophylaxis.
D000368:Aged; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004087:Dihydroergotamine / Q000494:pharmacology; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D005998:Glycine / Q000494:pharmacology / Q000627:therapeutic use*; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D000970:Antineoplastic Agents; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; C041593:godamed; C031388:heparin-dihydergot; D004087:Dihydroergotamine; D004054:Diethylstilbestrol; D006493:Heparin; C004955:fosfestrol; D001241:Aspirin; D005998:Glycine
Klinische Wertigkeit von Thrombozytenaggregationshemmern bei Ostrogen-Stoss-Therapie.